UA42719C2 - Compositions and methods for the treatment of immunomediated inflammatory disorders - Google Patents

Compositions and methods for the treatment of immunomediated inflammatory disorders

Info

Publication number
UA42719C2
UA42719C2 UA95104466A UA95104466A UA42719C2 UA 42719 C2 UA42719 C2 UA 42719C2 UA 95104466 A UA95104466 A UA 95104466A UA 95104466 A UA95104466 A UA 95104466A UA 42719 C2 UA42719 C2 UA 42719C2
Authority
UA
Ukraine
Prior art keywords
compositions
treatment
methods
inflammatory disorders
immunomediated inflammatory
Prior art date
Application number
UA95104466A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Керрі Спеар
Керри Спеар
Чарльз Джонсон
Хайнц Гшвенд
Original Assignee
Аксіз Фармасьютікелз, Інк
Аксиз Фармасьютикелз, Инк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аксіз Фармасьютікелз, Інк, Аксиз Фармасьютикелз, Инк filed Critical Аксіз Фармасьютікелз, Інк
Publication of UA42719C2 publication Critical patent/UA42719C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Compositions and methods for the prevention and treatment of immunomediated inflammatory disorders, especially for those disorders associated with the respiratory tract, are provided. More particularly, a tryptase inhibitor, typically a hydroxyaroyl or hydroxyheteroaroyl substituted dipeptide, is administered. Also provided by this invention are pharmaceutical compositions, typically aerosol or topical, as well as aerosol devices for administering these compositions intranasally.
UA95104466A 1993-03-12 1994-03-11 Compositions and methods for the treatment of immunomediated inflammatory disorders UA42719C2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3077093A 1993-03-12 1993-03-12
US3118793A 1993-03-12 1993-03-12
PCT/US1994/002706 WO1994020527A1 (en) 1993-03-12 1994-03-11 Compositions and methods for the treatment of immunomediated inflammatory disorders

Publications (1)

Publication Number Publication Date
UA42719C2 true UA42719C2 (en) 2001-11-15

Family

ID=26706445

Family Applications (1)

Application Number Title Priority Date Filing Date
UA95104466A UA42719C2 (en) 1993-03-12 1994-03-11 Compositions and methods for the treatment of immunomediated inflammatory disorders

Country Status (11)

Country Link
EP (1) EP0688337A1 (en)
JP (1) JPH08507768A (en)
KR (1) KR100309616B1 (en)
CN (2) CN1057772C (en)
AU (1) AU683459B2 (en)
CZ (1) CZ289930B6 (en)
FI (1) FI954245A (en)
PL (1) PL176941B1 (en)
SK (1) SK282537B6 (en)
UA (1) UA42719C2 (en)
WO (1) WO1994020527A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE189211T1 (en) * 1994-06-01 2000-02-15 Axys Pharm Inc COMPOSITIONS AND METHODS FOR TREATING DISEASES CAUSED BY MAST CELLS
WO1996009297A1 (en) 1994-09-23 1996-03-28 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell inflammatory condition
WO1997037969A1 (en) 1996-04-10 1997-10-16 Ono Pharmaceutical Co., Ltd. Tryptase inhibitor and novel guanidino derivatives
CZ29799A3 (en) * 1996-07-30 1999-06-16 Arris Pharmaceutical Corporation Disubstituted cyclic compound, process of its preparation, pharmaceutical composition containing thereof and method of treating disease of animal
WO1998024886A1 (en) * 1996-12-04 1998-06-11 Brigham And Women's Hospital, Inc. Mast cell protease that cleaves fibrinogen
WO1998033812A1 (en) * 1997-02-05 1998-08-06 Brigham And Women's Hospital, Inc. Mast cell protease peptide inhibitors
AU1208999A (en) * 1997-11-10 1999-05-31 Array Biopharma, Inc. Compounds which inhibit tryptase activity
US6221914B1 (en) * 1997-11-10 2001-04-24 Array Biopharma Inc. Sulfonamide bridging compounds that inhibit tryptase activity
WO1999026925A1 (en) * 1997-11-26 1999-06-03 Yoshitomi Pharmaceutical Industries, Ltd. Tryptase inhibitors comprising heterocyclic amide compounds
SE515982C2 (en) * 1998-03-06 2001-11-05 Lipocore Holding Ab Use of an oil-in-water emulsion as carrier for preparing a topical cream or lotion
SE9800729L (en) * 1998-03-06 1999-09-07 Scotia Lipidteknik Ab New topical formulation I
DE19939910A1 (en) * 1999-08-23 2001-03-01 Morphochem Ag New compounds that inhibit tryptase activity
GB0507577D0 (en) * 2005-04-14 2005-05-18 Novartis Ag Organic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201863A (en) * 1974-11-08 1980-05-06 Mitsubishi Chemical Industries, Limited N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4456595A (en) * 1982-12-06 1984-06-26 E. R. Squibb & Sons, Inc. Carboxy and substituted carboxy aroly peptides

Also Published As

Publication number Publication date
PL310559A1 (en) 1995-12-27
EP0688337A1 (en) 1995-12-27
KR100309616B1 (en) 2002-02-28
FI954245A (en) 1995-09-28
AU6364794A (en) 1994-09-26
PL176941B1 (en) 1999-08-31
CN1057772C (en) 2000-10-25
SK112995A3 (en) 1996-10-02
CZ232195A3 (en) 1996-07-17
CZ289930B6 (en) 2002-04-17
JPH08507768A (en) 1996-08-20
CN1234229A (en) 1999-11-10
CN1119019A (en) 1996-03-20
FI954245A0 (en) 1995-09-11
AU683459B2 (en) 1997-11-13
SK282537B6 (en) 2002-10-08
WO1994020527A1 (en) 1994-09-15

Similar Documents

Publication Publication Date Title
AU3153097A (en) Pharmaceutical for treatment of neurological and neuropsychiatric disorders
EP0923376A4 (en) Treatment of asthma and airway diseases
HK1062677A1 (en) 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
GB0129260D0 (en) Pharmaceutical compositions and their uses
IL159299A0 (en) Orally administered dosage forms of gaba analog prodrugs having reduced toxicity
TW329387B (en) Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
ZA943744B (en) Therapeutic substituted guanidines
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
CA2427227A1 (en) Lactam compound
UA42719C2 (en) Compositions and methods for the treatment of immunomediated inflammatory disorders
HUP0202862A2 (en) Pharmaceutical composition containing novel combination of loteprednol and antihistamines
UA41355C2 (en) Agent for treating neuro-aids
PL330910A1 (en) Mode of administering inhibitors of h+, k+ - atpase
EP1032556A4 (en) Pharmaceutically active compounds and methods of use
GB0130677D0 (en) Medicaments and novel compounds
GB9103764D0 (en) Compositions
IL143985A0 (en) New use of melagatran
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
BG106548A (en) Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog
BG102667A (en) Diosgenine-containing composition
IL105475A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 1a, 24(R) - DIHYDROXY-22(E)-DEHYDRO- VITAMIN D3 FOR TREATING OSTEOPOROSIS
PL370361A1 (en) Alkyl urea retinoid agonists i
TW325997B (en) Pharmaceutical composition for preventing and treating retinal diseases
MY128529A (en) Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
TW366284B (en) Pharmaceutical antitussive composition of delta-receptor antagonist